Human Birth Tissue Manufacturer Prepares for Submission of Investigational New Drug Applications and Transition into a Biologics Provider
Miami, FL – September 23, 2019 – TissueTechTM, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products, today announced the appointment of Jerry Chang, PhD to the position of Vice President of Product Development. In this new role, Dr. Chang will have oversight for ensuring the efficiency and integrity of all Product Lifecycle Management activities and will control the processes and testing of biological products for human use as the Company moves closer to commercialization of its birth tissue products as biologics.
Dr. Chang is tasked with overseeing all Product Lifecycle Management processes. This includes establishing strategies to optimize and deliver processes, analytics and formulations for the manufacturing of regenerative human birth tissue products within a Good Manufacturing Practice (GMP) environment to ensure that the company continues to produce and supply consistent products.
“Dr. Chang’s arrival represents an important addition to our Executive Team and under his leadership, we will be optimally suited to further scale up based on our strong research foundation,” said Scheffer C.G. Tseng, MD, PhD, TissueTech Chief Technology Officer and Co-founder. “And with the development of product pipeline programs that he is creating, we will continue to innovate and build new best-in-class manufacturing efficiencies,” he added.
Dr. Chang brings more than 30 years of experience in leadership, clinical product commercialization, research and development, and biotechnology to TissueTech. Prior to joining the TissueTech, he held executive-level positions at BoneSupport AB, Zimmer Biomet, and Johnson and Johnson driving growth, safety, quality, and cost effectiveness. He obtained his bachelor’s of science degree in chemistry from Northeast Louisiana University and his Ph.D. in Organic and Polymer Chemistry from the University of Cincinnati.
“Working in a cross-functional capacity at TissueTech is proving to be an amazing experience,” said Chang. “The results of our collaborative efforts are providing more therapeutic options to our physician customers and their patients – resulting in better outcomes. And that makes me very happy,” he added.
About TissueTech, Inc.
TissueTech is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care and soft tissue products to support regenerative tissue healing using amniotic membrane and umbilical cord birth tissue donated from healthy, pre-screened mothers after elective cesarean section delivery of a live birth. The organization brings a skilled approach to innovation in evidence-based medicine with more than 20 years of clinical experience and more than 30 years of scientific research funded by the National Institutes of Health. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at www.tissuetech.com.